Theromics Appoints Andrew C. Zeringue as Chief Executive Officer

WEST BRIDGEWATER, Mass.--(BUSINESS WIRE)--May 21, 2026--

Theromics Inc., a biotechnology company advancing the field of ablation therapeutics for minimally invasive cancer treatment, today announced the appointment of Andrew C. Zeringue as Chief Executive Officer. Andrew brings nearly two decades of expertise in interventional oncology, thermal ablation and the commercialization of innovative medical technologies. He has a proven track record of advancing emerging technologies from FDA clearance, to early commercialization through scalable market adoption.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521206781/en/

"We reviewed many candidates for this position and Andrew's extensive experience in interventional oncology and thermal ablation quickly distinguished him as the right choice to steer Theromics into its next chapter," said Joseph Amaral, M.D., Chairman of the Board of Theromics. "Under Andrew's leadership we are confident the company is well positioned to advance its platform technologies toward commercialization and deliver innovative solutions that help physicians address cancer treatment challenges, including reducing the risk of local cancer recurrence."

Theromics is focused on developing innovative biomaterial technologies designed to support more predictable energy delivery and improved treatment consistency in minimally invasive cancer therapies, including technologies intended to help address the challenge of local tumor recurrence following ablation procedures. The company is currently advancing its HeatSYNC™ gel platform, designed to enhance thermal energy transfer within soft tissue during ablation procedures, toward FDA clearance and clinical adoption.

Andrew has held senior leadership roles at companies developing and commercializing innovative interventional oncology and thermal ablation products including Quantum Surgical, NeuWave Medical (Ethicon-a subsidiary of Johnson & Johnson) BTG (acquired by Boston Scientific) and AngioDynamics. Throughout his career, he has played a key role in scaling multiple first-in-category platforms and has worked extensively with physicians, academic medical centers, health systems, and executive leadership teams to advance emerging technologies through commercialization and clinical adoption. Andrew is also co-founder of MedTech Angels, a physician- and operator-led investment group focused on supporting early-stage FDA-regulated medical device companies.

"I believe Theromics is uniquely positioned to help advance the next generation of local tumor therapy," said Andrew C. Zeringue. "Local recurrence following minimally invasive cancer treatment remains a significant clinical challenge, and Theromics is developing technologies designed to support more effective and predictable therapy delivery. The company’s founders are internationally recognized thought leaders in interventional oncology, and I am honored to join them in their mission to reduce recurrences following ablation therapy through the field of ablation therapeutics."

About Theromics Inc.

Theromics is a biotechnology company advancing the field of ablation therapeutics for minimally invasive cancer treatment. The company’s proprietary HeatSYNC™ and CryoSYNC™ biomaterial platforms are designed to enhance energy transfer within soft tissue to support more predictable energy delivery, improved treatment consistency and more effective local therapy. Theromics is also developing future applications that combine localized therapeutics with thermal ablation through its TACT™ (Thermally Activated Combination Therapy) platform, with the goal of improving local treatment outcomes while reducing systemic exposure associated with traditional therapies.

Andrew C. Zeringue, Chief Executive Officer, Theromics Inc.

WASHINGTON (AP) — The U.S. Commission of Fine Arts on Thursday approved the design for the triumphal arch that President Donald Trump wants built at an entrance to the nation's capital.

Commissioners, all of whom were appointed by Trump, approved the design despite overwhelming opposition from the public. Approval is a key step in the project's process.

The proposed arch is one of several projects the Republican president is pursuing alongside a White House ballroom to leave his imprint on Washington.

He has said some of his other projects, such as adding a blue coating to the interior of the Lincoln Memorial Reflecting Pool, will beautify the city in time for July 4 celebrations of America's 250th birthday.

The U.S. Commission of Fine Arts approved the concept for the arch at its monthly meeting in April.

As presented to the federal agency, the arch itself would stand 250 feet tall (76 meters) from its base to a torch held aloft by a Lady Liberty-like figure on top of the structure. The statue would be flanked on top by two eagles and guarded at the base by four lions — all gilded. The phrases “One Nation Under God” and “Liberty and Justice for All” would be inscribed in gold lettering atop either side of the monument.

A public observation deck on top would provide 360-degree views of the surroundings.

The commission’s vice chairman, architect James McCrery II, said in April that he preferred the arch without the figures on top. Removing them would significantly reduce the arch's height by about 80 feet (24.4 meters). Critics of the project, including an overwhelming number of people who submitted public comment in April, said the arch would be taller than any other monument in the capital city and dominate the skyline.

At a height of 250 feet, the arch would dwarf the Lincoln Memorial, which is 99 feet (30 meters) tall, and be close to half the height of the Washington Monument, an obelisk that is about 555 feet (169 meters) tall.

McCrery also recommended that the lions on the base be removed because that animal is “not a beast natural to the North American continent.” And he objected to plans for an underground tunnel for pedestrians to get to the arch, which would be built on a traffic circle between the Lincoln Memorial and Arlington National Cemetery in Virginia.

Preliminary surveys and testing of the site began last week.

A group of veterans and a historian have sued the Trump administration in federal court to block construction on grounds that the arch would disrupt the sightline between the Lincoln Memorial and Arlington House at Arlington National Cemetery, among other reasons.

Trump and Interior Secretary Doug Burgum have argued that Washington is the only major Western world capital without such an arch. Burgum's department includes the National Park Service, which manages the plot where Trump wants to put the arch.

Trump's rehab of the Lincoln Memorial Reflecting Pool is also the subject of a court challenge brought by The Cultural Landscape Foundation, which said the administration’s moves to repaint the bottom of the Reflecting Pool blue without first undergoing relevant reviews ran afoul of federal preservation laws governing historic sites.

The nonprofit group argued in a lawsuit filed last week that the changes at the Reflecting Pool are part of Trump’s broader effort to push through dramatic renovations in Washington without proper reviews and undermine the tone of the area.

A hearing in the case was scheduled for Thursday afternoon in federal court in Washington.

The Memorial Circle, where President Donald Trump has proposed building an arch to commemorate the United States' 250th anniversary is seen, Tuesday, May 19, 2026, in Washington. (AP Photo/Alex Brandon)